Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Change in Cash (2016 - 2025)

Historic Change in Cash for Gyre Therapeutics (GYRE) over the last 17 years, with Q3 2025 value amounting to $3.9 million.

  • Gyre Therapeutics' Change in Cash rose 179307.36% to $3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.5 million, marking a year-over-year increase of 34024.28%. This contributed to the annual value of -$21.7 million for FY2024, which is 36033.12% down from last year.
  • According to the latest figures from Q3 2025, Gyre Therapeutics' Change in Cash is $3.9 million, which was up 179307.36% from $21.4 million recorded in Q2 2025.
  • In the past 5 years, Gyre Therapeutics' Change in Cash ranged from a high of $52.7 million in Q1 2021 and a low of -$52.3 million during Q3 2022
  • For the 5-year period, Gyre Therapeutics' Change in Cash averaged around $1.3 million, with its median value being -$231000.0 (2024).
  • As far as peak fluctuations go, Gyre Therapeutics' Change in Cash crashed by 37239.29% in 2021, and later skyrocketed by 179307.36% in 2025.
  • Quarter analysis of 5 years shows Gyre Therapeutics' Change in Cash stood at -$14.8 million in 2021, then skyrocketed by 209.58% to $16.2 million in 2022, then plummeted by 54.22% to $7.4 million in 2023, then tumbled by 154.55% to -$4.1 million in 2024, then soared by 196.5% to $3.9 million in 2025.
  • Its Change in Cash stands at $3.9 million for Q3 2025, versus $21.4 million for Q2 2025 and $3.2 million for Q1 2025.